Table 3 Univariate analysis of quality indicators related to satisfaction (SUCE)

6

Delay in referral to specialized care

−0.26 (−1.33;0.81)

7

Late diagnosis of HIV in specialized care

−0.23 (− 0.81;0.35)

8

HIV diagnosis with previous negative serology

−0.10 (− 0.65;0.44)

10

Complementary tests in the initial assessment

0.01 (−1.07;1.10)

11

HIV plasma viral load

–

12

Determination of lymphocyte subpopulations (CD4)

–

13

Health education at initial assessment

0.24 (−0.06;0.54)

15

Indication of treatment with < 350 CD4 and without prior ART

–

16

Periodicity of visits (regular follow-up)

0.62 (0.13;1.11)*

17

Basic renal study in HIV+ patients

−0.57 (− 2.49;1.35)

20

LTI detection

0.09 (−0.27;0.44)

21

Vaccination against hepatitis A

1.14 (0.16;2.12)*

22

Vaccination against hepatitis B

0.49 (−0.41;1.40)

23

Vaccination against pneumococcal infection

0.74 (0.10;1.38)*

24

Prophylaxis against Pneumocystis jirovecii and Toxoplasma

−0.14 (−3.03;2.76)

25

Treatment and prevention of smoking

0.11 (−0.52;0.75)

26

Alcohol intake assessment

−1.20 (− 1.97; −0.44)*

29

Syphilis screening

0.03 (−0.35;0.41)

30

LTI treatment

−0.60 (−2.18;0.98)

35

Adaptation of initial ART guidelines to the guidelines

–

36

Initiation of ART in patients with symptomatic B/C events

–

37

First visit after the establishment of ART

−0.69 (−1.61;0.23)

38

Undetectable viral load (< 50 copies/ml) at week 48

−0.62 (−2.76;1.52)

39

Treatment with Abacavir (ABC) without previous HLA-B 5701

–

40

Treatment changes during the first year

−0.08 (− 0.87;0.71)

41

Record of adherence to treatment

0.33 (− 0.14;0.79)

42

Study of resistance in case of virologic failure

−0.48 (−1.85;0.90)

45

ART in pregnant women with HIV

–

47

Vertical transmission incidence

–

49

Evaluation by CHILD or MELD for chronic liver disease

1.67 (−1.34;4.67)

50

Evaluation of the hepatitis C virus coinfection

–

54

HBsAg patients receiving effective treatment

–

55

Ultrasound control in cirrhotic patients

1.25 (−3.23;5.73)

56

Cardiovascular risk assessment

−0.01 (− 0.34;0.31)